Over the past decades, myriad research groups and pharmaceutical companies have made great efforts to develop novel pharmaceutical compounds that could potently and specifically inhibit DNA-PK to potentiate IR-induced cytotoxicity in radioresistant neoplasms. Here, PRKDC is linked to neoplasm.